Fosfestrol

Fosfestrol
Clinical data
Trade names	Honvan, others
Other names	Diethylstilbestrol diphosphate; Stilbestrol diphosphate; DESDP; DESP; DES-DP; DES-P
AHFS/Drugs.com	International Drug Names
Routes of; administration	Intravenous, by mouth
Drug class	Nonsteroidal estrogen; Estrogen ester
ATC code	L02AA04 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name [4-[4-(4-phosphonooxyphenyl)hex-3-en-3-yl]phenoxy]phosphonic acid;
CAS Number	522-40-7 ; 4719-75-9 (tetrasodium);
PubChem CID	3032325;
ChemSpider	2297327 ;
UNII	A0E0NMA80F;
KEGG	D00946 ;
ChEMBL	ChEMBL1200598 ;
CompTox Dashboard (EPA)	DTXSID3046906 ;
ECHA InfoCard	100.007.573
Chemical and physical data
Formula	C18H22O8P2
Molar mass	428.314 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=P(Oc1ccc(cc1)\C(=C(\c2ccc(OP(=O)(O)O)cc2)CC)CC)(O)O;
	InChI InChI=1S/C18H22O8P2/c1-3-17(13-5-9-15(10-6-13)25-27(19,20)21)18(4-2)14-7-11-16(12-8-14)26-28(22,23)24/h5-12H,3-4H2,1-2H3,(H2,19,20,21)(H2,22,23,24)/b18-17+ ; Key:NLORYLAYLIXTID-ISLYRVAYSA-N ;
	(verify)

Fosfestrol, sold under the brand name Honvan and also known as diethylstilbestrol diphosphate (DESDP), is an estrogen medication which is used in the treatment of prostate cancer in men. It is given by slow intravenous infusion once per day to once per week or by mouth once per day.

Side effects of fosfestrol include nausea and vomiting, cardiovascular complications, blood clots, edema, and genital skin reactions, among others. Fosfestrol is an estrogen, and hence is an agonist of the estrogen receptor, the biological target of estrogens like estradiol. It acts as a prodrug of diethylstilbestrol.

Fosfestrol was patented in 1941 and was introduced for medical use in 1955. It was previously marketed widely throughout the world, but now remains available in only a few countries.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.